NYSE:BHVN - Biohaven Pharmaceutical Stock Price, Forecast & News

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) issued its quarterly earnings data on Friday, November, 1st. The company reported ($2.04) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.57) by $0.47. View Biohaven Pharmaceutical's Earnings History.

Biohaven Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Biohaven Pharmaceutical.

12 Wall Street analysts have issued twelve-month price targets for Biohaven Pharmaceutical's shares. Their forecasts range from $50.00 to $100.00. On average, they anticipate Biohaven Pharmaceutical's share price to reach $73.55 in the next twelve months. This suggests a possible upside of 32.6% from the stock's current price. View Analyst Price Targets for Biohaven Pharmaceutical.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biohaven Pharmaceutical.

News articles about BHVN stock have trended positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biohaven Pharmaceutical earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Biohaven Pharmaceutical.

Biohaven Pharmaceutical saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 6,230,000 shares, a decline of 6.9% from the December 15th total of 6,690,000 shares. Based on an average daily trading volume, of 613,600 shares, the short-interest ratio is presently 10.2 days. Approximately 14.5% of the shares of the stock are sold short. View Biohaven Pharmaceutical's Current Options Chain.

Some companies that are related to Biohaven Pharmaceutical include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), The Medicines (MDCO), Horizon Therapeutics (HZNP), ACADIA Pharmaceuticals (ACAD) and Reata Pharmaceuticals (RETA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Netflix (NFLX), Global Blood Therapeutics (GBT), Roku (ROKU), Sarepta Therapeutics (SRPT) and ACADIA Pharmaceuticals (ACAD).

(BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include California Public Employees Retirement System (0.27%), Rhenman & Partners Asset Management AB (0.24%), Columbus Circle Investors (0.05%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), Canton Hathaway LLC (0.01%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.

BHVN stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, California Public Employees Retirement System, Columbus Circle Investors, Canton Hathaway LLC, Zurcher Kantonalbank Zurich Cantonalbank and Nisa Investment Advisors LLC. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BHVN stock can currently be purchased for approximately $55.46.

Biohaven Pharmaceutical has a market capitalization of $2.90 billion. The company earns $-240,920,000.00 in net income (profit) each year or ($6.15) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe.View Additional Information About Biohaven Pharmaceutical.

The official website for Biohaven Pharmaceutical is http://www.biohavenpharma.com/.

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.